연구동향 분석

The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty

김성우 김영배 이정은 김나리 이원경 구재균 김은정 정선희 정우영 2017년

논문상세정보
인용/피인용

' The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty' 의 참고문헌

  • 한국 청소년 여성에서의 비정상 사춘기 발달
    이미화 Obstetrics & Gynecology Science 52 12 1197-1203 [2009]
  • 한국 소아청소년의 비만 유병률 추이: 1997년과 2005년 비교
    오경원 Korean Journal of Pediatrics 51 9 950-955 [2008]
  • Variations in pattern of pubertal changes in girls
    Marshall WA Arch Dis Child 44 291-303 [1969]
  • Treatment with gonadotropinreleasing hormone analogues: different impact on body weight in normal-weight and overweight children
    Wolters B Horm Res Paediatr 78 304-311 [2012]
  • Treatment of central precocious puberty with Gonadotropin- Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment
    Messaaoui A Rev Med Brux 26 27-32 [2005]
  • Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades
    Lazar L J Clin Endocrinol Metab 100 1445-1451 [2015]
  • Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index
    Rosenfield RL Pediatrics 123 84-88 [2009]
  • The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration
    Parent AS Endocr Rev 24 668-693 [2003]
  • The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study
    Magiakou MA J Clin Endocrinol Metab 95 109-117 [2010]
  • Standards for children's height at ages 2-9 years allowing for heights of parents
    Tanner JM Arch Dis Child 45 755-762 [1970]
  • Reproductive axis after discontinuation of gonadotropinreleasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
    Feuillan PP J Clin Endocrinol Metab 84 44-49 [1999]
  • Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty
    Arrigo T Eur J Endocrinol 150 533-537 [2004]
  • Radiologic atlas of skeletal development of the hand and wrist
    Greulich WW - [1959]
  • Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone
    Pescovitz OH J Clin Endocrinol Metab 67 474-479 [1988]
  • Precocious puberty and body composition: effects of GnRH analog treatment
    Chiumello G J Pediatr Endocrinol Metab 13 Suppl 1 791-794 [2000]
  • Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy
    van der Sluis IM J Clin Endocrinol Metab 87 506-512 [2002]
  • Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function
    Heger S J Clin Endocrinol Metab 84 4583-4590 [1999]
  • Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function
    Pasquino AM J Clin Endocrinol Metab 93 190-195 [2008]
  • Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty
    Palmert MR J Clin Endocrinol Metab 84 4480-4488 [1999]
  • Influence of GnRH analog therapy on body mass in central precocious puberty
    Głab E Pediatr Endocrinol Diabetes Metab 15 7-11 [2009]
  • Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment
    Colmenares A Int J Pediatr Endocrinol 2014 5- [2014]
  • Gonadotropin-releasing hormone agonist therapy and obesity in girls
    Shiasi Arani K Int J Endocrinol Metab 13 e23085- [2015]
  • Final height in central precocious puberty after long term treatment with a slow release GnRH agonist
    Oostdijk W Arch Dis Child 75 292-297 [1996]
  • Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty
    Carel JC J Clin Endocrinol Metab 84 1973-1978 [1999]
  • Effects of Gonadotropin-Releasing Hormone Agonist Therapy on Body Mass Index and Height in Girls with Central Precocious Puberty
    이승재 전남의대학술지 48 1 27-31 [2012]
  • Earlier onset of puberty in girls: relation to increased body mass index and race.
    Kaplowitz P.B Pediatrics 108 347-353 [2001]
  • Clinical practice: precocious puberty
    Carel JC N Engl J Med 358 2366-2377 [2008]
  • Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist
    Ko JH Horm Res Paediatr 75 174-179 [2011]
  • Central precocious puberty. An overview of diagnosis, treatment, and outcome.
    Lee P.A Endocrinol Metab Clin North Am 28 901-918 [1999]
  • Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty
    Boot AM J Clin Endocrinol Metab 83 370-373 [1998]
  • 2007 Korean National Growth Charts: review of developmental process and an outlook
    Moon JS Korean J Pediatr 51 1-25 [2008]